Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical innovation company focused on developing high-impact therapies for cardiovascular disease, with lead programs including BackBeat CNT, a cardiac neuromodulation therapy targeting hypertension, and Virtue SAB, a sirolimus-eluting bioresorbable scaffold for coronary artery disease. The company became publicly traded in 2023 following a de-SPAC business combination and has since operated as a clinical-stage medical device company working toward regulatory approval milestones in the United States and Europe. OBIO's most recent annual report on Form 10-K was filed with the SEC on March 12, 2026, reflecting fiscal year 2025 activity. The company operates within the medical devices and cardiovascular therapeutics sector. For comprehensive deal history, clinical milestone tracking, and post-merger financial data on OBIO and hundreds of other SPAC transactions, sign up for full access at SpacDesk.